盐酸伊托必利联合奥美拉唑治疗反流性食管炎疗效及对胃肠激素和表皮生长因子受体水平的影响

Clinical Effect of Itopride Hydrochloride Combined with Omeprazole in Treating Reflux Esophagitis and Its Effects on the Levels of Gastrointestinal Hormones and Epidermal Growth Factor Receptor

目的观察盐酸伊托必利联合奥美拉唑治疗反流性食管炎(RE)的临床疗效及对血清胃泌素(GAS)、黏膜血管活性肠肽(VIP)和表皮生长因子受体(EGFR)水平的影响。方法将医院收治的96例RE患者随机分为治疗组和对照组,各48例。治疗组给予盐酸伊托必利+奥美拉唑治疗,对照组给予盐酸伊托必利+法莫替丁治疗,均持续2个月。结果治疗组总有效率和EGFR阳性率分别为95.83%和68.75%,显著大于对照组的81.25%和31.25%(P<0.05);两组GAS水平均较治疗前上升,VIP水平均较治疗前降低,且治疗组改变幅度更大(P<0.05),两组患者各项症状评分均较治疗前降低,且治疗组降低幅度大于对照组(P<0.05)。结论盐酸伊托必利联合奥美拉唑治疗RE疗效显著,可改善相关症状,并对GAS和VIP水平及EGFR表达有一定调节作用。

Objective To observe the clinical effect of itopride hydrochloride combined with omeprazole in treating reflux esophagitis（ RE） and its effect on serum gastrin（ GAS）,mucosal vasoactive intestinal peptide（ VIP） and epidermal growth factor receptor（ EGFR）.Methods Totally 96 patients with RE admitted to our hospital were randomly divided into the treatment group and the control group,48 cases in each group. The treatment group was treated with itopride hydrochloride combined with omeprazole,while the control group was treated with itopride hydrochloride combined with famotidine,and treatment in the two groups lasted for 2 months. Results The total effective rate and the positive expression rate of EGFR in the treatment group were 95. 83% and 68. 75%,which were significantly higher than 81. 25% and 31. 25% in the control group（ P 〈 0. 05）. After treatment,the GAS levels in the two groups were increased,while the VIP levels in the two groups were decreased,and the improvement in the treatment group was more significant（ P 〈 0. 05）.The scores of different symptoms in the two groups were decreased,and the decrease in the treatment group was more significant（ P 〈 0. 05）.Conclusion Itopride hydrochloride combined with omeprazole in the treatment of RE has a significant effect,which can improve the related symptoms and regulate the levels of GAS and VIP and the expression of EGFR.